LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: CAR T-Cell Therapy: Updates in Nursing Management.

    Baer, Brittney

    Clinical journal of oncology nursing

    2021  Volume 25, Issue 3, Page(s) 255–258

    Abstract: Chimeric antigen receptor (CAR) T-cell therapy is an evolving treatment used for hematologic malignancies; it requires specialized nursing care and knowledge. This article discusses updates in the nursing management of CAR T-cell therapies and their use ... ...

    Abstract Chimeric antigen receptor (CAR) T-cell therapy is an evolving treatment used for hematologic malignancies; it requires specialized nursing care and knowledge. This article discusses updates in the nursing management of CAR T-cell therapies and their use in adult patients. A comprehensive review of the literature, including peer-reviewed articles and pharmaceutical drug labels, was conducted. Oncology and intensive care unit nurses will need to be knowledgeable about and remain current in the management of patients receiving CAR T-cell therapies because they pose different challenges than seen with traditional chemotherapy regimens.
    MeSH term(s) Hematologic Neoplasms/therapy ; Humans ; Immunotherapy, Adoptive ; Intensive Care Units ; Nursing Care ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Chemical Substances Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2021-06-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2014665-6
    ISSN 1538-067X ; 1092-1095
    ISSN (online) 1538-067X
    ISSN 1092-1095
    DOI 10.1188/21.CJON.255-258
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5229: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 390: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Response to "CAR T-Cell Therapy: Updates in Nursing Management".

    Groff, Pat / Baer, Brittney

    Clinical journal of oncology nursing

    2021  Volume 25, Issue 5, Page(s) 496

    Abstract: I have found Clinical Journal of Oncology Nursing (CJON) articles to be enlightening and well written, and I look forward to reading CJON monthly to expand my general cancer care knowledge. I have been a blood and marrow transplantation (BMT) nurse since ...

    Abstract I have found Clinical Journal of Oncology Nursing (CJON) articles to be enlightening and well written, and I look forward to reading CJON monthly to expand my general cancer care knowledge. I have been a blood and marrow transplantation (BMT) nurse since 1976; our BMT program birthed the chimeric antigen receptor (CAR) T-cell program. In October 2020, I retired as a BMT supervisor and policy keeper from the Seattle Cancer Care Alliance (SCCA), so I am very familiar with both specialties. I was lucky to spend my career at the Fred Hutchinson Cancer Research Center (FHCRC), which has emphasized research at its core. Clinical nutrition research has been a mainstay since the beginning of the program.
    MeSH term(s) Humans ; Immunotherapy, Adoptive ; Neoplasms/therapy ; Oncology Nursing ; Receptors, Chimeric Antigen ; T-Lymphocytes
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2021-09-17
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2014665-6
    ISSN 1538-067X ; 1092-1095
    ISSN (online) 1538-067X
    ISSN 1092-1095
    DOI 10.1188/21.CJON.496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5229: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 390: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Management Principles Associated With Cytokine Release Syndrome.

    Baer, Brittney / Dudley, Channing Vail / Simons, Rhea Micci

    Seminars in oncology nursing

    2019  Volume 35, Issue 5, Page(s) 150931

    Abstract: Objective: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS).: Data sources: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, ... ...

    Abstract Objective: To discuss current recommendations and resources for nurses to ensure they advocate for patients with cytokine release syndrome (CRS).
    Data sources: A literature search using key terms: cytokine release syndrome, neurotoxicity, CAR T, adverse events.
    Conclusion: Chimeric antigen receptor (CAR) T-cell immunotherapy is a growing and rapidly changing field of research. Prompt recognition and management of the side effects of CAR T-cell therapy is pivotal to the safe outcomes of patients. As patients are treated with these novel therapies, additional recommendations and standards for treating CRS and neurotoxicity will occur.
    Implication for nursing practice: Nursing plays a pivotal role in the CAR T patients' treatment course because they are the first line of defense in the care of these patients. Providers and patients both rely on nursing knowledge and training to recognize symptoms of CRS and neurotoxicity. With the early recognition of the signs and symptoms of CRS and neurotoxicity, nursing will help improve the outcomes of the patients receiving CAR T-cell therapy.
    MeSH term(s) Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/therapy ; Humans ; Immunotherapy, Adoptive/adverse effects ; Neoplasms/immunology ; Neoplasms/therapy ; Oncology Nursing/methods ; Receptors, Antigen, T-Cell/drug effects ; Receptors, Chimeric Antigen/therapeutic use
    Chemical Substances Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2019-08-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 632682-1
    ISSN 1878-3449 ; 0749-2081
    ISSN (online) 1878-3449
    ISSN 0749-2081
    DOI 10.1016/j.soncn.2019.08.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2849: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.

    Dudley, Channing Vail / Baer, Brittney / Simons, Rhea Micci

    Seminars in oncology nursing

    2019  Volume 35, Issue 5, Page(s) 150930

    Abstract: Objective: To discuss the mechanism of action and nursing care of adults receiving chimeric antigen receptor (CAR) T-cell therapy.: Data source: Peer reviewed articles and pharmaceutical drug labels.: Conclusion: CAR T-cell therapy is among the ... ...

    Abstract Objective: To discuss the mechanism of action and nursing care of adults receiving chimeric antigen receptor (CAR) T-cell therapy.
    Data source: Peer reviewed articles and pharmaceutical drug labels.
    Conclusion: CAR T-cell therapy is among the most exciting therapies in the evolution of cancer treatment. The efficacy of research with CAR T-cell therapy has shown promising results in hematologic malignancies as well as in solid tumors.
    Implications for nursing practice: Understanding the complexity of care for these patients from the bedside to the outpatient setting is vital for their survival and quality of care.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Immunotherapy/methods ; Immunotherapy, Adoptive/methods ; Male ; Middle Aged ; Neoplasms/immunology ; Neoplasms/therapy ; Oncology Nursing/methods ; Receptors, Antigen, T-Cell/drug effects ; Receptors, Chimeric Antigen/therapeutic use
    Chemical Substances Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2019-09-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 632682-1
    ISSN 1878-3449 ; 0749-2081
    ISSN (online) 1878-3449
    ISSN 0749-2081
    DOI 10.1016/j.soncn.2019.08.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2849: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration.

    Gatwood, Katie S / Dholaria, Bhagirathbhai R / Lucena, Mariana / Baer, Brittney / Savani, Bipin N / Oluwole, Olalekan O

    EJHaem

    2021  Volume 3, Issue Suppl 1, Page(s) 54–60

    Abstract: Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T-cell therapy (CART), have demonstrated impressive efficacy ... ...

    Abstract Adoptive cellular therapy has made a landmark change within the treatment paradigm of several hematologic malignancies, and novel cellular therapy products, such as chimeric antigen receptor T-cell therapy (CART), have demonstrated impressive efficacy and produced durable responses. However, the CART treatment process is associated with significant toxicities, healthcare resource utilization, and financial burden. Most of these therapies have been administered in the inpatient setting due to their toxicity profile. Improved toxicity management strategies and a better understanding of cellular therapy processes are now established. Therefore, efforts to transition CART to the outpatient setting are warranted with the potential to translate into enhanced patient quality of life and cost savings. A successful launch of outpatient CART requires several components including a multidisciplinary cellular therapy team and an outpatient center with appropriate clinical space and personnel. Telemedicine should be incorporated for closer monitoring. Additionally, clear criteria for admission upon clinical decompensation, a pathway for prompt inpatient transition, and clear toxicity management guidelines should be implemented. Effective education about cellular therapy and toxicity management is imperative, especially for the Emergency Department and Intensive Care Unit teams. Here, we have outlined the various logistical and clinical considerations required for the care of CART patients, which will aid centers to establish an outpatient CART program.
    Language English
    Publishing date 2021-11-19
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2688-6146
    ISSN (online) 2688-6146
    DOI 10.1002/jha2.333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

    Oluwole, Olalekan O / Dholaria, Bhagirathbhai / Knight, Tristan E / Jain, Tania / Locke, Frederick L / Ramsdell, Linda / Nikiforow, Sarah / Hashmi, Hamza / Mooney, Kathy / Bhaskar, Shakthi T / Morris, Katrina / Gatwood, Katie / Baer, Brittney / Anderson, Larry D / Hamadani, Mehdi

    Transplantation and cellular therapy

    2023  Volume 30, Issue 2, Page(s) 131–142

    Abstract: The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As ... ...

    Abstract The first series of chimeric antigen receptor T (CAR-T) cell therapy products were approved in 2017 to 2019 and have shown remarkable efficacy in both clinical trials and the real-world setting, but at the cost of prolonged patient hospitalization. As the toxicity management protocols were refined, the concept of cellular therapy administered in the outpatient setting gained steam, and single institutions began to perform certain aspects of CAR-T monitoring in the outpatient setting for select patients. However, there are many considerations for a successful outpatient program. In anticipation of increasing use of CAR-T-cell therapy in the outpatient setting as a mechanism to overcome frequent hospital bed shortages and high cost of inpatient care, the American Society for Transplantation and Cellular Therapy convened a group of experts in hematology, oncology, and cellular therapy to provide a comprehensive review of the existing publications on outpatient CAR-T cell therapy, discuss selected ongoing clinical trials of outpatient CAR-T, and describe strategies to optimize safety without compromising efficacy for patients treated and monitored in the outpatient setting.
    MeSH term(s) Humans ; United States ; Receptors, Chimeric Antigen/therapeutic use ; Outpatients ; Immunotherapy, Adoptive/adverse effects ; Societies ; Cell- and Tissue-Based Therapy
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2023-11-10
    Publishing country United States
    Document type Review ; Practice Guideline
    ZDB-ID 3062231-1
    ISSN 2666-6367
    ISSN (online) 2666-6367
    DOI 10.1016/j.jtct.2023.11.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5082: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.

    Dholaria, Bhagirathbhai / Mehraban, Nasima / Baer, Brittney / Long, Nancy / Jayani, Reena V / Byrne, Michael T / Kassim, Adetola A / Engelhardt, Brian G / Savani, Bipin N / Oluwole, Olalekan O

    British journal of haematology

    2022  Volume 198, Issue 6, Page(s) 1073–1075

    MeSH term(s) Antigens, CD19 ; Biological Products ; Feasibility Studies ; Humans ; Immunotherapy, Adoptive ; Lymphoma, Large B-Cell, Diffuse ; Outpatients ; Receptors, Chimeric Antigen ; Telemedicine
    Chemical Substances Antigens, CD19 ; Biological Products ; Receptors, Chimeric Antigen ; brexucabtagene autoleucel (4MD2J2T8SJ) ; axicabtagene ciloleucel (U2I8T43Y7R)
    Language English
    Publishing date 2022-06-28
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.18339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.182: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top